



## Who do we (not) have to treat?

Sergio Serrano-Villar

Department of Infectious Diseases

Hospital Universitario Ramón y Cajal. Madrid

# To Treat or Not to Treat?


**the ANCHOR study**  
 ABOUT THE STUDY | FREQUENTLY ASKED QUESTIONS | STUDY SITES | JOIN THE STUDY

**LIVING WITH HIV HAS GOTTEN A LOT EASIER. WITH LONGER LIFESPANS, HOWEVER, WE FACE A NEW SET OF CHALLENGES.**

Anal cancer rates are rising among people living with HIV. The goal of the ANCHOR study is to find the best way to prevent anal cancer among HIV positive men and women. During a screening visit, you will be screened for pre-cancerous anal lesions. If lesions are found, you will be enrolled and randomized to either have the lesions treated or monitored every six months. Both groups will be followed for a minimum of five years. You will be compensated \$100 for the screening visit.

We need HIV+ volunteers of all genders who are 35+ to take part in a pilot study to prevent anal cancer.

**FIND AN ANCHOR STUDY SITE**



# Natural history of anal dysplasia



Tong W, *et al.* Progression to and spontaneous regression of high-grade anal squamous intraepithelial lesions in HIV-infected and uninfected men. *AIDS* 2013

Mathews WC, *et al.* Natural History of Anal Dysplasia in an HIV-Infected Clinical Care Cohort: Estimates Using Multi-State Markov Modeling. *PLoS ONE*. 2014. 9(8):e104116

Jongen VW *et al.* Anal Squamous Intraepithelial Lesions (SILs) in Human Immunodeficiency Virus-Positive Men Who Have Sex With Men: Incidence and Risk Factors of SIL and of Progression and Clearance of Low-Grade SILs. *J Infect Dis*. 2020;222(1):62.

Machalek DA, *et al.* *Lancet Oncol*. 2012;13(5):487.

Goldstone S, *et al.* Five-year cumulative incidence of invasive anal cancer among HIV-infected patients according to baseline anal cytology results: an inception cohort analysis. *HIV Med* 2015; 16:191–5.

Fazendin EA, *et al.* Condyloma acuminatum, anal intraepithelial neoplasia, and anal cancer in the setting of HIV: do we really understand the risk? *Dis Colon Rectum* 2017; 60:1078–82

Mette T. Faber *et al.* Risk of Anal Cancer Following Benign Anal Disease and Anal Cancer Precursor Lesions: A Danish Nationwide Cohort Study, *Cancer Epidemiol Biomarkers Prev* 2020


Poynten *et al.* The Natural History of Anal High-grade Squamous Intraepithelial Lesions in Gay and Bisexual Men. *Clin Infect Dis*. 2021 Mar 1;72(5):853-861.

# Case 1

40 year-old transgender woman.  
HIV+, on ART, CD4 >500, HPV16+, 18+, other HR +.



June 2020: Condylomatosis



**November 2021: Verrucous carcinoma**



## Case 2

53 yo MSM with HIV on ART.

Recurrent circumferential condilomatosis (surgery x3).

HPV16+, 18-, other HR+.



Feb 2020: condilomatosis, LSIL, hyperkeratosis



**July 2022:**  
**Squamous cell carcinoma**

## Case 3

69 yo MSM with HIV, on ART, CD4 900/uL.  
HPV16+, 18+, other HR+.



August 2022: First visit, anal complaints

**Biopsies: Scamous cell carcinoma**

# Case 4

53 yo MSM on ART  
HPV16+, 18-, other HR+



August 2022: Condyloma exeresis, Bx at 11: HSIL extension down to rectal glands. Cannot rule out infiltration

**Surgery: Scamous cell carcinoma**



# Case 5


- 75 yo woman, not sexually active, referred from GI specialist.
- Follow-up colonoscopy due to past history of colonic polyps reveals intranal HSIL.
- No comorbidities
- No prior history of anogenital HPV disease.
- HPV 33+, anal cytology: LSIL
- Normal HRA



The majority of anal cancers occur in persons without pre-defined risk factors, and a large retrospective cohort study of a Kaiser Permanente database found previous HSIL to be one of the strongest risk factors for subsequent development of SCC.




# Towards a Unified Anal Cancer Risk Scale



# Risk factors for HSIL progression


**Viral factors**



HPV 16

# HPV16 is responsible of the largest fraction of anal cancers

- HPV 16 is enriched in HSIL and anal cancer lesions.
- HPV 16 associated with 75-89% of all anal cancers in cross-sectional studies from tissue banking.
- The fraction of anal cancer attributable to HPV16 is smaller in PWH.
- By far the most carcinogenic HPV type.




Lin C, Franceschi S, Clifford GM. Human papillomavirus types from infection to cancer in the anus, according to sex and HIV status: a systematic review and meta-analysis. Lancet Infect Dis. 2018 Feb;18(2):198-206. doi: 10.1016/S1473-3099(17)30653-9. Epub 2017 Nov 17. PMID: 29158102; PMCID: PMC5805865.

Roldán Urgoiti GB, et al. The prognostic value of HPV status and p16 expression in patients with carcinoma of the anal canal. PLoS One 2014; 9:e108790. 67. Alemany L, Saunier M, et al.; HPV VVAP Study Group. Human papillomavirus DNA prevalence and type distribution in anal carcinomas worldwide. Int J Cancer 2015; 136:98–107. 68. Valmary-Degano S, et al. Signature patterns of human papillomavirus type 16 in invasive anal carcinoma. Hum Pathol 2013; 44:992–1002.



# Risk factors for HSIL progression

## Viral factors



HPV 16

## Environmental factors



MSM



HIV



Aging



IDU



Smoking



Solid-organ transplant



# Predictors of HSIL regression

- Age < 45 years old
- HPV16 clearance
- Smaller lesion size
- AIN2 instead of AIN3
- Stronger HPV-specific CD4+ T cell response


**Markers of  
stronger  
immune  
responses  
against HPV**



**We need markers/an algorithm to distinguish HSIL that requires treatment vs HSIL that can be monitored.**

# Risk factors for HSIL progression

## Viral factors



HPV 16

## Environmental factors



MSM




HIV



Aging



IDU



Smoking



Solid-organ transplant

## Genetic factors



History of  
anogenital  
HPV disease



Recalcitrant  
condylomas  
(DOCK8 deficiency)



HPV-discordant couples



# Recurrent HPV disease and Genetic susceptibility

## DOCK8 deficiency

36 y/o African-American man with Hx:

- Recalcitrant genital condylomas (age 20) s/p recurrent hematuria and pyelonephritis requiring urethral diversion.
- Further extension of penile lesions and poor wound healing -> penectomy (age 31)
- HPV-related SCC in situ in upper and lower extremities bilaterally, invasive disease in 4th finger



# Clinical discordance between stable sexually active couples: Genetic susceptibility?

**Patient 1: MSM with HIV on ART, CD4 >500,  
HPV 16+**



**Patient 2 (his partner): MSM with HIV on ART,  
CD4 >500, HPV 16+**



**Besides the HPV type and the risk group,  
how can we better capture the risk of HSIL  
progression to anal cancer?**



# Cumulative information



Anal cytologies and HRA repeatedly normal  
Absence of high risk HPV over time  
Long-term treatment response



Cytologic HSIL despite “normal” HRA  
Persistent HPV16  
Refractory/recurrent HSIL

Abnormal HRA



HSIL diagnosed



Successful treatment



**HRA patterns: Does a circumferencial HSIL is clinically equivalent to a HSIL diagnosed during random biopsies?**





# Progression of anal high-grade squamous intraepithelial lesions to invasive anal cancer among HIV-infected men who have sex with men

J. Michael Berry<sup>1</sup>, Naomi Jay<sup>1</sup>, Ross D. Cranston<sup>2</sup>, Teresa M. Darragh<sup>3</sup>, Elizabeth A. Holly<sup>4</sup>, Mark L. Welton<sup>5</sup> and Joel M. Palefsky<sup>1</sup>

<sup>1</sup>Department of Medicine, University of California San Francisco, San Francisco, CA

<sup>2</sup>Department of Medicine, University of Pittsburgh, Pittsburgh, PA

<sup>3</sup>Department of Pathology, University of California San Francisco, San Francisco, CA

<sup>4</sup>Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA

<sup>5</sup>Department of Surgery, Stanford University, Stanford, CA




Figure 2. (a) Case 6. Arrow indicates anal high-grade squamous intraepithelial lesion (HSIL) biopsied in May 2001 at the end of Anal Neoplasia Study. Patient lost to follow-up. (b) The same man presented with a palpable mass in June 2002 in exactly the same area as previously biopsied HSIL; arrow indicates invasive squamous cell carcinoma (SCCA). [Color figure can be viewed in the online issue, which is available at [wileyonlinelibrary.com](http://wileyonlinelibrary.com).]

- Retrospective study of **138 cases of anal cancer** (1997-2011).
- Although diffuse multifocal HSIL was present in 21 (**15%**) men, only three men developed simultaneous multifocal cancers.
- Six of 27 study participants had discrete lesions



# Current algorithm to capture the risk of HSIL progression

## *Fiat secundum artem*



Enema, Galenic texts  
129 dC



Hemorrhoidectomy  
Salerno school  
XII century



DARE  
Middle age



Hemorrhoid  
cauterization  
XV century



Delfos oracle  
2022

# Wishlist - #1 – Biomarkers of HSIL progression

## Microbiota-based SCReening of Anal Cancer in PWH (SCRATCH)



- **Study period: 2018-2022**
- **N=300, test and validation cohorts**
- **Primary aim:**
  - Identify in MSM with HIV anal-associated bacterial biomarkers to improve the accuracy of anal cytology for the diagnosis of biopsy-proven HSIL.
  - Potential bacterial biomarkers: bacteria, proteins and metabolites.




# Wishlist - #1 – Biomarkers of HSIL progression

## Microbiota-based SCReening of Anal Cancer in PWH (SCRATCH)

### METHODS

Population: 213 MSM with HIV undergoing HSIL screening in 4 clinical sites in Spain and Italy




- Discovery cohort: 167 (70 with confirmed HSIL)
- Validation cohort: 46 (25 with confirmed HSIL)



# Wishlist - #1 – Biomarkers of HSIL progression

## Microbiota-based SCReening of Anal Cancer in PWH (SCRATCH)

### RESULTS









# Wishlist - #1 – Biomarkers of HSIL progression

## Microbiota-based SCReening of Anal Cancer in PWH (SCRATCH)

### RESULTS



**Net reclassification index: 44%**  
(benefit from the metabolic test)

# Wishlist - #2 – Move beyond acetic and Lugol staining

## Narrow Band Imaging (NBI)


### Origin of ectocervix glycogen staining with iodine




Paul Erlich  
1854 – 1915  
Physiologist  
Nobel Prize 1908



Walter Schiller  
(1887-1960)  
Pathologist



### Esophagus



### Colon



The computer-aided classification system yielded a detection accuracy of 97.8% (363/371); sensitivity and specificity of types B-C3 lesions for a diagnosis of neoplastic lesion were 97.8% (317/324) and 97.9% (46/47), respectively

Takemura Y et al. Computer-aided system for predicting the histology of colorectal tumors by using narrow-band imaging magnifying colonoscopy. *Gastrointestinal endoscopy* 2012; 75: 179-185.


Hajelssedig *et al.* Diagnostic accuracy of narrow-band imaging endoscopy with targeted biopsies compared with standard endoscopy with random biopsies in patients with Barrett's esophagus: A systematic review and meta-analysis. *Gastroenterol Hepatol.* 2021 Oct;36(10):2659-2671



# Wishlist - #2 – Move beyond acetic and Lugol staining


## Detection of anal dysplasia is enhanced by NBI and acetic acid

- 60 patients with abnormal anal cytology
- Endoscopic anorectal examination
- Biopsies from abnormal regions in 58 cases.
- SIL 41/60 demonstrated: 28 LSIL, 13 HSIL.
- Acetic acid + NBI was able to detect more lesions than acetic acid or NBI alone.



# Wishlist - #3 – Nomograms for anal cancer risk

## Need nomograms to prioritize patients for anal cancer screening



AUC 0.63



# Wishlist - #4 – Facilitate AI takeover

Need to develop for AI-based HRA



Thanks to Dr. Crespillo and Dr. Ron, our next-gen anoscopist taking over

## Clinical Gastroenterology and Hepatology

CLINICAL – ALIMENTARY TRACT | ARTICLES IN PRESS

### Artificial Intelligence–Assisted Colonoscopy for Colorectal Cancer Screening: A Multicenter Randomized Controlled Trial

Hong Xu • Raymond S.Y. Tang • Thomas Y.T. Lam • ... Zhenshi Ye • Zhang Shutian • Joseph J.Y. Sung

Show all authors • Show footnotes

#### Conclusions

In this multicenter RCT in asymptomatic patients, AI-assisted colonoscopy improved overall ADR, advanced ADR, and ADR of both expert and nonexpert attending endoscopists. (ClinicalTrials.gov, Number: NCT04422548).



#### ARTICLE

<https://doi.org/10.1038/s43887-021-00443-8>

OPEN

### Accurate recognition of colorectal cancer with semi-supervised deep learning on pathological images

Gang Yu<sup>1</sup>, Kai Sun<sup>1</sup>, Chao Xu<sup>2</sup>, Xing-Hua Shi<sup>3</sup>, Chong Wu<sup>4</sup>, Ting Xie<sup>1</sup>, Run-Qi Meng<sup>5</sup>, Xiang-He Meng<sup>6</sup>, Kuan-Song Wang<sup>7</sup>, Hong-Mei Xiao<sup>8</sup> & Hong-Wen Deng<sup>6,8</sup>

# Who do we (not) have to treat?



## Treat everyone



## Prioritize people for HSIL screening and treatment based on anal cancer incidence

1. PWH: MSM, >45 years, women with previous genital HPV disease
2. Other causes of immunosuppression
3. Use cumulative information: recurrent HSIL lesions, persistent HPV16



## Promote highly collaborative research

- Discover markers of HSIL progression: large biobanks in prospective cohorts with enough number of cancers
- Nomograms to stratify anal cancer risk
- Understand better the clinical significance of HSIL patterns
- Facilitate AI: massive prospective image repositories





# THANK YOU!!



[serranovillar@gmail.com](mailto:serranovillar@gmail.com)



[@serranovillar](https://twitter.com/serranovillar)  
[@infecciosasryc](https://twitter.com/infecciosasryc)